Atacicept: Targeting B cells in multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 3, Issue 4, 2010, Pages 205-216

  Hartung, Hans Peter ^a   Kieseier, Bernd C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

atacicept; B cells; B lymphocytes; immunotherapies; multiple sclerosis; treatment

Indexed keywords

APRIL PROTEIN; ATACICEPT; AUTOANTIBODY; B CELL ACTIVATING FACTOR; PLACEBO; RITUXIMAB;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CELL LINEAGE; CELL MATURATION; CELL SURVIVAL; CHRONIC PYELONEPHRITIS; CLINICAL TRIAL; DRUG BINDING; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; INJECTION SITE REACTION; LOADING DRUG DOSE; MEMORY CELL; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT;

EID: 77954950402     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285610371146     Document Type: Review

References (90)

1. Anolik, J. and Sanz, I. ( 2004) B cells in human and murine systemic lupus erythematosus. Curr Opin Rheumatol 16: 505-512.
2. Archelos, J.J., Storch, M.K. and Hartung, H.P. ( 2000) The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol 47: 694-706.
3. Barcellos, L.F., Oksenberg, J.R., Begovich, A.B., Martin, E.R., Schmidt, S., Vittinghoff, E. et al. (2003) HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 72: 710-716.
4. Benson, M.J., Dillon, S.R., Castigli, E., Geha, R.S., Xu, S., Lam, K.P. et al. (2008) Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180: 3655-3659.
5. Brinkmann, V. ( 2009) FTY 720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Brit J Pharmacol 158: 1173-1182.
6. Brown, B.A., Kantesaria, P.P. and McDevitt, L.M. ( 2007) Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother 41: 1660-1668.
7. Carbonatto, M., Yu, P., Bertolino, M., Vigna, E., Steidler, S., Fava, L. et al. (2008) Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol Sci 105: 200-210.
8. Castigli, E., Wilson, S.A., Garibyan, L., Rachid, R., Bonilla, F., Schneider, L. et al. (2005 a) TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 37: 829-834.
9. Castigli, E., Wilson, S.A., Scott, S., Dedeoglu, F., Xu, S., Lam, K.P. et al. (2005 b) TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 201: 35-39.
10. Cepok, S., Rosche, B., Grummel, V., Vogel, F., Zhou, D., Sayn, J. et al. (2005) Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128: 1667-1676.
11. Chitnis, T. ( 2007) The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol 79: 43-72.
12. Chofflon, M. ( 2005) Mechanisms of action for treatments in multiple sclerosis: does a heterogeneous disease demand a multi-targeted therapeutic approach ? BioDrugs 19: 299-308.
13. Chun, J. and Hartung, H.-P. ( 2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33: 91-101.
14. Cohen, J.A., Barkhoff, F., Comi, G., Hartung, H.P., Katri, O.B., Montalban, X. et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402-415.
15. Coles, A.J., Compston, D.A., Selmaj, K.W., Lake, S.L., Moran, S., Margolin, D.H. et al. (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786-1801.
16. Corcione, A., Casazza, S., Ferretti, E., Giunti, D., Zappia, E., Pistorio, A. et al. (2004) Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A 101: 11064-11069.
17. Cree, B. ( 2006) Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 12: 171-178.
18. Cross, A.H., Stark, J.L., Lauber, J., Ramsbottom, M.J. and Lyons, J.A. ( 2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180: 63-70.
19. Dall'Era, M., Chakravarty, E., Wallace, D., Genovese, M., Weisman, M., Kavanaugh, A. et al. (2007) Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56: 4142-4150.
20. Delgado, S. and Sheremata, W.A. ( 2006) The role of CD4+ T-cells in the development of MS. Neurol Res 28: 245-249.
21. Dillon, S.R., Gross, J.A., Ansell, S.M. and Novak, A.J. ( 2006) An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5: 235-246.
22. Do, R.K., Hatada, E., Lee, H., Tourigny, M.R., Hilbert, D., Chen-Kiang, S. et al. (2000) Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 192: 953-964.
23. Fisher, J.B., Jacobs, D.A., Markowitz, C.E., Galetta, S.L., Volpe, N.J., Nano-Schiavi, M.L. et al. (2006) Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113: 324-332.
24. Franciotta, D., Salvetti, M., Lolli, F., Serafini, B. and Aloisi, F. ( 2008) B cells and multiple sclerosis. Lancet Neurol 7: 852-858.
25. Frohman, E., Costello, F., Zivadinov, R., Stuve, O., Conger, A., Winslow, H. et al. (2006) Optical coherence tomography in multiple sclerosis. Lancet Neurol 5: 853-863.
26. Genovese, M.C., Kaine, J.L., Lowenstein, M.B., Del Giudice, J., Baldassare, A., Schechtman, J. et al. (2008) Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I / II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 58: 2652-2661.
27. Gordon-Lipkin, E., Chodkowski, B., Reich, D.S., Smith, S.A., Pulicken, M., Balcer, L.J., Frohman, E.M. et al. (2007) Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 69: 1603-1609.
28. Gross, J.A., Dillon, S.R., Mudri, S., Johnston, J., Littau, A., Roque, R. et al. (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 15: 289-302.
29. Gross, J.A., Johnston, J., Mudri, S., Enselman, R., Dillon, S.R., Madden, K. et al. (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404: 995-999.
30. Handel, A.E., Giovannono G., Ebers, G.E. and Ramagopalan S.V. (2010) Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol 6: 156-166.
31. Hauser, S.L., Waubant, E., Arnold, D.L., Vollmer, T., Antel, J., Fox, R.J. et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676-688.
32. Hawker, K. ( 2008) B-cell targeted treatment for multiple sclerosis: mechanism of action and clinical data. Curr Opin Neurol 21(Suppl 1): S19-S25.
33. Heffernan, J., Burleson, F., Roque, R., Waggie, K., Carbonatto, M., Ponce, R. et al. (2008) The evaluation of atacicept on protective immunity in the mouse streptococcal host resistance model (abstract 1934). Toxicologist 102: 398.
34. Hemmer, B., Archelos, J.J. and Hartung, H.P. ( 2002) New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3: 291-301.
35. Hemmer, B. and Hartung, H.P. ( 2007) Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol 62: 314-326.
36. Hemmer, B. and Stüve, O. ( 2007) Revised criteria for neuromyelitis optica - a new diagnostic standard? Nat Clin Pract Neurol 3: 132-133.
37. Hohlfeld, R. and Wekerle, H. ( 2004) Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A 101(Suppl 2): 14599-14606.
38. Hohlfeld, R. and Wiendl, H. ( 2001) The ups and downs of multiple sclerosis therapeutics. Ann Neurol 49: 281-284.
39. Hsu, B.L., Harless, S.M., Lindsley, R.C., Hilbert, D.M. and Cancro, M.P. ( 2002) Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 168: 5993-5996.
40. Huntington, N.D., Tomioka, R., Clavarino, C., Chow, A.M., Liñares, D., Maña, P. et al. (2006) A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol 18: 1473-1485.
41. Kalled, S.L. ( 2005) The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 204: 43-54.
42. Kerschensteiner, M., Gallmeier, E., Behrens, L., Leal, V.V., Misgeld, T., Klinkert, W.E. et al. (1999) Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189: 865-870.
43. Kolln, J., Ren, H.M., Da, R.R., Zhang, Y., Spillner, E., Olek, M. et al. (2006) Triosephosphate isomerase- and glyceraldehyde-3-phosphate dehydrogenase-reactive autoantibodies in the cerebrospinal fluid of patients with multiple sclerosis. J Immunol 177: 5652-5658.
44. Kornek, B., Storch, M.K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T. et al. (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157: 267-276.
45. Krumbholz, M., Theil, D., Cepok, S., Hemmer, B., Kivisäkk, P., Ransohoff, R.M. et al. (2006) Chemokines in multiple sclerosis: CXCL 12 and CXCL 13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129: 200-211.
46. Krumbholz, M., Theil, D., Derfuss, T., Rosenwald, A., Schrader, F., Monoranu, C.M. et al. (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201: 195-200.
47. Lambracht-Washington, D., O'Connor, K.C., Cameron, E.M., Jowdry, A., Ward, E.S., Frohman, E. et al. (2007) Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS. J Neuroimmunol 186: 164-176.
48. Lassmann, H., Bruck, W. and Lucchinetti, C.F. ( 2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17: 210-218.
49. Liossis, S.N. and Sfikakis, P.P. ( 2008) Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 127: 280-285.
50. Lucchinetti, C., Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., Lassmann, H. et al. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47: 707-717.
51. MacKay, F. and Tangye, S.G. ( 2004) The role of the BAFF / APRIL system in B cell homeostasis and lymphoid cancers. Curr Opin Pharmacol 4: 347-354.
52. MacKay, F., Woodcock, S.A., Lawton, P., Ambrose, C., Baetscher, M., Schneider, P. et al. (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190: 1697-1710.
53. Magliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M. et al. (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130: 1089-1104.
54. Marrie, R.A. ( 2004) Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 3: 709-718.
55. Marsters, S.A., Yan, M., Pitti, R.M., Haas, P.E., Dixit, V.M., Ashkenazi, A. et al. (2000) Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 10: 785-788.
56. Martinez-Gamboa, L., Brezinschek, H.P., Burmester, G.R. and Dorner, T. ( 2006) Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy. Autoimmun Rev 5: 437-442.
57. McDole, J., Johnson, A.J. and Pirko, I. ( 2006) The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis. Neurol Res 28: 256-261.
58. Medana, I., Martinic, M.A., Wekerle, H. and Neumann, H. ( 2001) Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 159: 809-815.
59. Munafo, A., Priestley, A., Nestorov, I., Visich, J. and Rogge, M. ( 2007) Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 63: 647-656.
60. Nestorov, I., Munafo, A., Papasouliotis, O. and Visich, J. ( 2008) Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 48: 406-417.
61. Nestorov, I., Papasouliotis, O., Pena-Rossi, C. and Munafo, A. (2010) Pharmakokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharmac Sci 99: 524-538.
62. Owens, G.P., Bennett, J.L., Gilden, D.H. and Burgoon, M.P. ( 2006) The B cell response in multiple sclerosis. Neurol Res 28: 236-244.
63. Pena-Rossi, C., Nasonov, E., Stanislav, M., Yakusevich, V., Ershova, O., Lomareva, N. et al. (2009) An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept on patients with systemic lupus erythematosus. Lupus 18: 547-555.
64. Perini, P., Ranzato, F., Calabrese, M., Battistin, L. and Gallo, P. ( 2006) Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry 77: 953-955.
65. Poser, C.M. ( 2006) The multiple sclerosis trait and the development of multiple sclerosis: genetic vulnerability and environmental effect. Clin Neurol Neurosurg 108: 227-233.
66. Prineas, J.W. and Graham, J.S. ( 1981) Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 10: 149-158.
67. Qin, Y., Duquette, P., Zhang, Y., Olek, M., Da, R.R., Richardson, J. et al. (2003) Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab Invest 83: 1081-1088.
68. Ramagopalan, S.V., Dyment, D.A. and Ebers, G.C. (2009) Environmental factors and their timing in adult-onset multiple sclerosis. Trends Neurosci 649: 1-8.
69. Roschke, V., Sosnovtseva, S., Ward, C.D., Hong, J.S., Smith, R., Albert, V. et al. (2002) BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 169: 4314-4321.
70. Schneider, P., MacKay, F., Steiner, V., Hofmann, K., Bodmer, J.L., Holler, N. et al. (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189: 1747-1756.
71. Scolding, N.J., Morgan, B.P., Houston, W.A., Linington, C., Campbell, A.K., Compston, D.A. et al. (1989) Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 339: 620-622.
72. Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E. and Aloisi, F. ( 2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14: 164-174.
73. Seshasayee, D., Valdez, P., Yan, M., Dixit, V.M., Tumas, D., Grewal, I.S. et al. (2003) Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18: 279-288.
74. Silverman, G.J. ( 2006) Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheum 54: 2356-2367.
75. Simpson, B.S. and Coles, A.J. ( 2007) Rationale for cytotoxic monoclonal antibodies in MS. Int MS J 14: 48-56.
76. Sospedra, M. and Martin, R. ( 2005) Immunology of multiple sclerosis. Annu Rev Immunol 23: 683-747.
77. Stüve, O., Leussink, V.I., Fröhlich R., Hemmer B., Hartung H.P., Menge T. and Kieseier, B.C. ( 2009) Long-term B lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 66: 259-261.
78. Svensson, L., Abdul-Majid, K.-B., Bauer, J., Lassmann, H., Harris, R.A., Holmdahl, R. et al. (2002) A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination. Eur J Immunol 32: 1939-1946.
79. Tak, P.P., Thurlings, R.M., Rossier, C., Nestorov, I., Dimic, A., Mircetic, V. et al. (2008) Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 58: 61-72.
80. Thangarajh, M., Gomes, A., Masterman, T., Hillert, J. and Hjelmstrom, P. ( 2004) Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol 152: 183-190.
81. Thangarajh, M., Masterman, T., Hillert, J., Moerk, S. and Jonsson, R. ( 2007) A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis. Scand J Immunol 65: 92-98.
82. Thangarajh, M., Masterman, T., Rot, U., Duvefelt, K., Brynedal, B., Karrenbauer, V.D. et al. (2005) Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J Neuroimmunol 167: 210-214.
83. Thompson, J.S., Bixler, S.A., Qian, F., Vora, K., Scott, M.L., Cachero, T.G. et al. (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293: 2108-2111.
84. Varfolomeev, E., Kischkel, F., Martin, F., Seshasayee, D., Wang, H., Lawrence, D. et al. (2004) APRIL-deficient mice have normal immune system development. Mol Cell Biol 24: 997-1006.
85. Villar, L.M., Sádaba, M.C., Roldán, E., Masjuan, J., González-Porqué, P., Villarrubia, N. et al. (2005) Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 115: 187-194.
86. Weinshenker, B.G., O'Brien, P.C., Petterson, T.M., Noseworthy, J.H., Lucchinetti, C.F., Dodick, D.W. et al. (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46: 878-886.
87. Willer, C.J., Dyment, D.A., Risch, N.J., Sadovnick, A.D. and Ebers, G.C. ( 2003) Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 100: 12877-12882.
88. Yan, M., Wang, H., Chan, B., Roose-Girma, M., Erickson, S., Baker, T. et al. (2001) Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2: 638-643.
89. Zeyda, M., Poglitsch, M., Geyeregger, R., Smolen, J.S., Zlabinger, G.J., Hörl, W.H. et al. (2005) Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 52: 2730-2739.
90. Zouali, M. ( 2008) B lymphocytes-chief players and therapeutic targets in autoimmune diseases. Front Biosci 13: 4852-4861.